CSIMarket
 
Tg Therapeutics Inc   (TGTX)
Other Ticker:  
 
 
Price: $15.2200 $-0.14 -0.911%
Day's High: $15.67 Week Perf: -7.03 %
Day's Low: $ 15.09 30 Day Perf: 7.26 %
Volume (M): 4,006 52 Wk High: $ 35.67
Volume (M$): $ 60,971 52 Wk Avg: $16.77
Open: $15.26 52 Wk Low: $6.46



 Market Capitalization (Millions $) 2,372
 Shares Outstanding (Millions) 156
 Employees 132
 Revenues (TTM) (Millions $) 190
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 41
 Capital Exp. (TTM) (Millions $) 0

Tg Therapeutics Inc
TG Therapeutics Inc. is a publicly-traded biopharmaceutical company based in New York City, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The company's pipeline consists of multiple product candidates, including small molecule inhibitors and monoclonal antibodies.

One of the company's most advanced product candidates is umbralisib, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase-1 epsilon (CK1e) that is being evaluated in clinical trials for the treatment of hematologic malignancies and solid tumors. The drug has demonstrated promising anti-tumor activity in early-phase studies and is currently in phase III development for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

TG Therapeutics also has a pipeline of monoclonal antibodies targeting B-cell-specific proteins, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody that targets the same protein as rituximab but has greater efficacy and reduced side effects. This drug, in combination with umbralisib, has shown potential in a phase III clinical trial for relapsed or refractory CLL/SLL.

The company's other product candidates include TG-1501, a monoclonal antibody that targets a B-cell receptor signaling protein, and TG-1701, a next-generation BTK inhibitor that is in preclinical development.

TG Therapeutics is also exploring the potential of its product candidates in other indications, such as multiple sclerosis and inflammatory bowel disease.

In addition to its drug development efforts, TG Therapeutics has also entered into partnerships and collaborations with other companies, academic institutions, and research organizations to advance the development of its product candidates and expand its pipeline.

Overall, TG Therapeutics is a cutting-edge biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. With a strong pipeline of product candidates and ongoing clinical trials, the company has the potential to make a significant impact on patient outcomes in these therapeutic areas.


   Company Address: 3020 Carrington Mill Blvd, Suite 475 Morrisville 27560 NC
   Company Phone Number: 554-4484   Stock Exchange / Ticker: NASDAQ TGTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

TG Therapeutics Presents Positive Data for BRIUMVI in Multiple Sclerosis at ACTRIMS Annual Forum

Published Fri, Mar 1 2024 12:30 PM UTC

TG Therapeutics, Inc. recently shared promising data from three Phase 3 trials assessing the efficacy of BRIUMVI (ublituximab-xiiy) in treating patients with relapsing forms of multiple sclerosis (RMS). The findings were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in West Palm Beach, Florida.:This article aims t...

Management Announcement

TG Therapeutics Surprises Market with Positive Net Revenue in Q4 2023, Despite Previous Losses

Published Wed, Jan 10 2024 12:01 PM UTC

Investigation Reveals TG Therapeutics' Positive Net Revenue in Fourth Quarter and Full Year 2023 Despite Previous Losses
TG Therapeutics, a biopharmaceutical company specializing in the development of innovative treatments, has announced preliminary net revenue figures for the fourth quarter and full year 2023. The company reported net product revenue of approximately $4...

Partnership

Advancing Allogeneic Therapies: TG Therapeutics and Precision BioSciences Drive CAR T Revolution Targeting Autoimmune Diseases for IND Filing by 2024

Published Tue, Jan 9 2024 12:00 PM UTC

In an announcement that holds the promise to magnetize significant attention in the field of biotechnology, TG Therapeutics, Inc. has avowed a worldwide licensing pact with Precision BioSciences, Inc. The focus of this strategic agreement is the development and commercialization of Precision's allogeneic Chimeric Antigen Receptor (CAR) T cell therapy program aimed at tacklin...

Tg Therapeutics Inc

TG Therapeutics Inc. Soars to New Heights with Unprecedented Revenue Growth and Profit Margin Increase

Financial News Report: TG Therapeutics Inc. Reports Strong Revenue Growth and Improved Profit Margins
TG Therapeutics Inc., a major player in the pharmaceutical preparations industry, has reported a significant turnaround in its financial performance. The company's revenue for the most recent fiscal period increased by a remarkable 176,298.936% year on year to reach $165.82 million. This notable revenue growth has surpassed the industry average, which stood at 3.18% during the same period.
Notably, TG Therapeutics Inc. has transitioned from a loss to income, with earnings per share (EPS) posting at $0.73. Compared to the prior reporting season, where EPS was at $-0.34 per share, this represents a notable improvement. Revenue has also shown an impressive increase of 931.573%, rising from $16.07 million to its current level.
In terms of profitability, TG Therapeutics Inc. has demonstrated significant improvements. The net margin for the fiscal period ending September 30, 2023, rose to 68.71%, indicating better management of expenses and increased efficiency. Additionally, the operating margin edged up to 69.22%, further highlighting the company's ability to generate profits.

Tg Therapeutics Inc

Despite Record-Setting Q2 Revenue Surge, TG Therapeutics Inc. Struggles with Profitability Challenges in 2023

Tg Therapeutics Inc is a pharmaceutical company that has shown impressive revenue growth in the second quarter of 2023. The company reported a revenue growth of 2606.061% year on year, reaching $16.07 million in the financial second quarter. However, despite this significant growth, Tg Therapeutics Inc also experienced an increased deficit per share at $-0.34.
The top-line surge in the second quarter of 2023 is a positive correlation with its Major Pharmaceutical Preparations sector peers, as they also experienced overall revenue growth of 2.20% in the same period. This indicates that Tg Therapeutics Inc is performing well and keeping pace with its industry competitors.






 

Tg Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com